Advertisement

Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid

  • G. Boman
Originals

Summary

Single oral doses of rifampicin (10 mg/kg body weight), p-aminosalicylic acid (0.2 g/kg), isoniazid (10 mg/kg), or rifampicin and either p-aminosalicylic acid or isoniazid, were given to 69 tuberculous patients with normal renal and hepatic function. Ten-fold interindividual differences were observed in the peak serum concentrations and half-lives of rifampicin; its half-life was reduced from 4.3 h after the first dose to 3.1 h after the third dose, possibly due to self-induction of its own metabolism. No effect on its serum concentration or half-life, nor on those of isoniazid, were found after simultaneous oral administration of the two drugs. After treatment with rifampicin and p-aminosalicylic acid, the peak serum level of the former was delayed from 2 to 4 h, it was reduced from 8.0 to 3.8 µg/ml, and the mean area under the serum concentration curve throughout the entire 8 h study period was also lowered by about half. Individual patients did not attain therapeutically effective peak serum concentrations of rifampicin if also treated withp-aminosalicylic acid. The interaction observed between the two drugs is probably due to impaired gastrointestinal absorption of rifampicin, either by alteration of its physico-chemical properties or by a decrease in the gastric emptying rate combined with more rapid intestinal transit. The combination of these two drugs is unsuitable for the routine chemotherapy of tuberculosis.

Key words

Rifampicin p-aminosalicylic acid drug interaction isoniazid pharmacokinetics antituberculous therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Acocella, G., Pagani, V., Marchetti, M., Baroni, G.C., Nicolis, F.B.: Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapia (Basel)16, 356–370 (1971)Google Scholar
  2. Acocella, G., Bonollo, L., Garimoldi, M., Mainardi, M., Tenconi, L.T., Nicolis, F.B.: Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut13, 47–53 (1972a)Google Scholar
  3. Acocella, G., Lamarina, A., Nicolis, F.B., Pagani, V., Segre, G.: Kinetic studies on rifampicin. II. Multicompartmental analysis of the serum, urine and bile concentrations in subjects treated for one week. Europ. J. clin. Pharmacol.5, 111–115 (1972b)Google Scholar
  4. Anonymous: 2000 papers on rifampicin. Milano: Gruppo Lepetit S.p.A. 1972Google Scholar
  5. Binda, G., Domenichini, E., Gottardi, A., Orlandi, B., Ortelli, E., Pacini, B., Fowst, G.: Rifampicin, a general review. Arzneimittel-Forsch.21, 1907–1978 (1971)Google Scholar
  6. Boman, G., Borgå, O., Hanngren, Å., Malmborg, A.-S. Sjöqvist F.: Pharmakokinetische und genetische Gesichtspunkte über den Metabolismus von Isoniazid, p-Aminosalicylsäure und Rifampicin. Pneumonologie (Suppl.) 15–20 (1970)Google Scholar
  7. Boman G. Hanngren Å. Malmborg A.-S. Borgå O. Sjöqvist, F.: Drug interaction: decreased serum concentrations of rifampicin when given with P.A.S. Lancet 1971I, 800Google Scholar
  8. Boman, G., Ringberger, V.-A.: Binding of rifampicin in human plasma. Europ. J. clin Pharmacol. In press (1974)Google Scholar
  9. Canetti, G., Djurovic, V., Le Lirzin, M., Thibier, R., Lepeuple, A.: Étude comparative de l'évolution des taux sanguins de rifampicine chez l'homme par deux méthodes microbiologiques différentes. Rev. Tuberc. (Paris)34, 93–106 (1970)Google Scholar
  10. Curci, G., Ninni, A., Di Mezza, F.: Indagini sperimentali sulla farmacocinetica della rifampicina. Arch. Tisiol.23, 293–314 (1968a)Google Scholar
  11. Curci, G., Ninni, A., D'Alessio, A., Iodice, F.: Interferenze fisico-chimiche a livello del legame proteico fra PAS ed altri chemioterapici. XIX Congresso Italiano di Tisiologia3, 955–957 (1968b)Google Scholar
  12. Curci, G., Bergamini, N., Delli Veneri, F., Ninni, A., Nitti, V.: Half-life of rifampicin after repeated administration of different doses in humans. Chemotherapia (Basel)17, 373–381 (1972)Google Scholar
  13. Ericsson, H.: Assay of antibiotics in small amounts of fluid. Scand. J. clin. Lab. Invest.12, 423–432 (1960)Google Scholar
  14. Halsted, C.H., McIntyre, P.A.: Intestinal malabsorption caused by aminosalicylic acid therapy. Arch. intern. Med.130, 935–939 (1972)Google Scholar
  15. Hanngren, Å., Borgå, O., Sjöqvist, F.: Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS). Scand. J. resp. Dis.51, 61–69 (1970)Google Scholar
  16. Heinevaara, O., Palva, I.P.: Malabsorption and defiency of vitamin B12 caused by treatment with para-aminosalicylic acid. Acta med. scand.177, 337–341 (1965)Google Scholar
  17. Jezequel, A.M., Orlandi, F., Tenconi, L.T.: Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes. Gut12, 984–987 (1971)Google Scholar
  18. Keberle, H.: Physico-chemical factors of drugs affecting absorption, distribution and excretion. Acta pharmacol. (Kbh.)29, Suppl 3, 30–47 (1971)Google Scholar
  19. Lal, S., Singhal, S.N., Burley, D.M., Crossley, G.: Effect of rifampicin and isoniazid on liver function. Brit. med. J.1972 I, 148–150Google Scholar
  20. Lehmann, J.: A micromethod for the determination of para-amino-salicylic acid (PAS) in blood, urine and other biological fluids. Scand. J. clin. Lab. Invest.3, 306–310 (1951)Google Scholar
  21. Levine, R.R.: Factors affecting gastrointestinal absorption of drugs. Digest. Dis.15, 171–188 (1970)Google Scholar
  22. Maggi, N., Furesz S., Pallanza, R., Pelizza, G.: Rifampicin desacetylation in the human organism. Arzneimittel-Forsch.19, 651–654 (1969)Google Scholar
  23. Maher, J.R., Whitney, J.M., Chambers, J.S., Stanonis, D.J.: The quantitative determination of isoniazid and para-amino-salicylic acid in body fluids. Amer. Rev. Tuberc.77, 852–861 (1957)Google Scholar
  24. Marche, J., Hugues, F.C., Graisely, B., Marche, C.: Les hépatites ictérigènes au cours des traitements associant isoniazide et rifampicine. Observations cliniques et expérimentales. Rev. Tuberc. (Paris)35, 55–76 (1971)Google Scholar
  25. Menz, H.P., von Oldershausen, H.F.: Blood serum levels and elimination of rifampicin in acute and chronic diseases of the liver. Adv. Antimicrob. Antineopl. Chemother., p. 95–97. München: Urban & Schwarzenberg 1972Google Scholar
  26. Oschkinat, F., Flemming, J.: Serum levels after administration of rifampicin. Respiration28, (Suppl.) 29–39 (1971)Google Scholar
  27. Porven, G., Canetti, G.: Les taux de rifampicine dans le sérum de l'homme. Rev. Tuberc. (Paris)32, 707–716 (1968)Google Scholar
  28. Riess, W.: The optimum dosage schedule for Rimactane. A Symposium on Rimactane, Basle, November 1968, p. 36–42. Basel: Ciba Ltd. 1968Google Scholar
  29. Schoene, B., Fleischmann, R.A., Remmer, H., von Oldershausen, H.F.: Induction of drug-metabolizing enzymes in human liver. Naunyn-Schmiedeberg's Arch. exp. Path. Pharmak.274, Suppl., R 101 (abstract) (1972)Google Scholar
  30. Scotti, R.: Sex difference in blood levels of some antibiotics. Chemotherapia (Basel)18, 205–211 (1973)Google Scholar
  31. Sjöqvist, F., Alexanderson, B.: Drug interactions. A critical look at their documentation and clinical importance. Proc. Europ. Soc. Study Drug Toxicity. Excerpta Med. Intern. Congr. Ser.254, 167–179 (1972)Google Scholar
  32. Verbist, L.: Rifampicin blood levels in man. Acta tuberc. pneumol. belg.60, 288–298 (1969)Google Scholar

Copyright information

© Springer-Verlag 1974

Authors and Affiliations

  • G. Boman
    • 1
    • 2
  1. 1.Department of Thoracic MedicineKarolinska HospitalStockholmSweden
  2. 2.Department of Clinical PharmacologyHuddinge HospitalStockholmSweden

Personalised recommendations